Barclays
NVCT icon

Barclays’s Nuvectis Pharma NVCT Stock Holding History

Barclays’s Portfolio NVCT Stock Details NVCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$56.3K Sell
3,061
-60
-2% -$672 ﹤0.01% 4278
2026
Q1 		$24.1K Sell
3,121
-21,064
-87% -$180K ﹤0.01% 4537
2025
Q4 		$183K Buy
24,185
+5,760
+31% +$37.5K ﹤0.01% 4367
2025
Q3 		$111K Sell
18,425
-4,749
-20% -$32.6K ﹤0.01% 4581
2025
Q2 		$173K Buy
23,174
+22,015
+1,899% +$200K ﹤0.01% 4369
2025
Q1 		$11.3K Buy
1,159
+15
+1% +$108 ﹤0.01% 4859
2024
Q4 		$6.19K Hold
1,144
– – ﹤0.01% 5040
2024
Q3 		$7.2K Sell
1,144
-7,126
-86% -$46.9K ﹤0.01% 5003
2024
Q2 		$52.3K Sell
8,270
-2,023
-20% -$13.8K ﹤0.01% 4194
2024
Q1 		$84.4K Buy
10,293
+39
+0.4% +$332 ﹤0.01% 4494
2023
Q4 		$85.5K Buy
10,254
+8,865
+638% +$79.1K ﹤0.01% 4671
2023
Q3 		$17.9K Buy
1,389
+18
+1% +$261 ﹤0.01% 4202
2023
Q2 		$21.9K Buy
+1,371
New +$21.9K ﹤0.01% 4118

Other funds holding NVCT

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
IAM
Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
OCM
Occam Crest Management Darien, Connecticut $193M AUM 233.09% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
BWP
Baldwin Wealth Partners Marion, Massachusetts $1.53B AUM 28.5% 1-Year Est. Return

Barclays's NVCT Position: Q2 2026 in Review

Barclays reduced its Nuvectis Pharma (NVCT) stake by 1.9% in Q2 2026, selling an estimated $672 and leaving 3,061 shares worth $56.3K. The position accounts for ﹤0.01% of the portfolio, ranked #4278.

Barclays first reported a position in NVCT in Q2 2023 and has held it in 13 quarters since. The position peaked at $183K in Q4 2025. 83 funds tracked by Wall St. Rank hold NVCT as of Q2 2026.

  • Barclays held 3,061 shares of Nuvectis Pharma worth $56.3K as of Q2 2026.
  • Barclays sold 60 Nuvectis Pharma shares in Q2 2026, an estimated $672.
  • Nuvectis Pharma made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #4278 holding.
  • Barclays first reported a position in Nuvectis Pharma in Q2 2023 and has held it in 13 quarters since.
  • Barclays's Nuvectis Pharma position peaked at $183K in Q4 2025.
  • 83 funds tracked by Wall St. Rank held Nuvectis Pharma as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.